Skip to main content
Skip to main content

AAP Gateway

Advanced Search »

User menu

  • Login
  • AAP Policy
  • Topic/Program Collections
  • Submit Manuscript
  • Alerts
  • Subscribe
  • aap.org

Menu

  • AAP Grand Rounds
  • AAP News
  • Hospital Pediatrics
  • NeoReviews
  • Pediatrics
  • Pediatrics in Review
  • Current AAP Policy
  • Journal CME
  • AAP Career Center
  • Pediatric Collections
  • AAP Journals Catalog

Sections

    • Login
    • AAP Policy
    • Topic/Program Collections
    • Submit Manuscript
    • Alerts
    • Subscribe
    • aap.org

    Get Involved! Pediatrics is accepting nominations for Editorial Board positions.

    Sign up for Insight Alerts highlighting editor-chosen studies with the greatest impact on clinical care.
    Video Abstracts -- brief videos summarizing key findings of new articles
    Watch the Features Video to learn more about Pediatrics.

    Advertising Disclaimer »

    A statement of reaffirmation for this policy was published at

    • 118(3):1266
    • 124(2):845
    • 135(2):e558

    This policy is a revision of the policy in

    • 91(5):1001

    Tools and Links

    Pediatrics
    July 2003, VOLUME 112 / ISSUE 1
    AMERICAN ACADEMY OF PEDIATRICS

    Controversies Concerning Vitamin K and the Newborn

    Committee on Fetus and Newborn
    • Article
    • Info & Metrics
    • Comments
    Loading
    Download PDF

    Abstract

    Prevention of early vitamin K deficiency bleeding (VKDB) of the newborn, with onset at birth to 2 weeks of age (formerly known as classic hemorrhagic disease of the newborn), by oral or parenteral administration of vitamin K is accepted practice. In contrast, late VKDB, with onset from 2 to 12 weeks of age, is most effectively prevented by parenteral administration of vitamin K. Earlier concern regarding a possible causal association between parenteral vitamin K and childhood cancer has not been substantiated. This revised statement presents updated recommendations for the use of vitamin K in the prevention of early and late VKDB.

    BACKGROUND

    Vitamin K deficiency may cause unexpected bleeding (0.25%–1.7% incidence) during the first week of life in previously healthy-appearing neonates (early vitamin K deficiency bleeding [VKDB] of the newborn [formerly known as classic hemorrhagic disease of the newborn]). The efficacy of neonatal vitamin K prophylaxis (oral or parenteral) in the prevention of early VKDB is firmly established. It has been the standard of care since the American Academy of Pediatrics recommended it in 1961.1

    Late VKDB, a syndrome defined as unexpected bleeding attributable to severe vitamin K deficiency in infants 2 to 12 weeks of age, occurs primarily in exclusively breastfed infants who have received no or inadequate neonatal vitamin K prophylaxis. In addition, infants who have intestinal malabsorption defects (cholestatic jaundice, cystic fibrosis, etc) may also have late VKDB. The rate of late VKDB (often manifesting as sudden central nervous system hemorrhage) ranges from 4.4 to 7.2 per 100 000 births, according to reports from Europe and Asia.2,3 When a single dose of oral vitamin K has been used for neonatal prophylaxis, the rate has decreased to 1.4 to 6.4 per 100 000 births. Parenteral neonatal vitamin K prophylaxis prevents the development of late VKDB in infants, with the rare exception of those with severe malabsorption syndromes.2

    Oral administration of vitamin K has been shown to have efficacy similar to that of parenteral administration in the prevention of early VKDB.4–6 However, several countries have reported a resurgence of late VKDB coincident with policies promoting the use of orally administered prophylaxis, even with multiple-dose regimens. In a 1997 review of these experiences by Cornelissen et al,7 surveillance data from 4 countries revealed oral prophylaxis failures of 1.2 to 1.8 per 100 000 live births, compared with no reported cases after intramuscular administration. Newborns receiving incomplete oral prophylaxis tended to have a higher risk of developing VKDB, with rates of approximately 2 to 4 per 100 000. Small daily oral doses, as practiced in the Netherlands, may decrease the risk of late VKDB8 and approach the efficacy of the parenteral route; however, this needs to be better studied.

    Draper and Stiller,9 using other data from Great Britain, have questioned the results of earlier studies of Golding et al10,11 that attempted to show an association between intramuscular vitamin K administration in newborns and an increased incidence of childhood cancer. Using data from the National Registry of Childhood Tumors, they estimated the cumulative incidence of childhood leukemia. Three sources of data, including the estimates from Golding et al, provided rates of intramuscular vitamin K use over the same time frame. Their analyses failed to show a correlation between increased use of intramuscular vitamin K and the incidence of childhood leukemia.

    The Vitamin K Ad Hoc Task Force of the American Academy of Pediatrics12 reviewed the reports of Golding et al and other information regarding the US experience13 and concluded that there was no association between the intramuscular administration of vitamin K and childhood leukemia or other cancers.

    Additional studies that have since been conducted by other investigators have not supported a clinical relationship between newborn parenteral administration of vitamin K and childhood cancer. Ross and Davies14 published a review of the evidence in 2000. They found no randomized or quasi-randomized evidence of an association between parenteral vitamin K prophylaxis and cancer in childhood. Ten case-control studies were identified, of which 7 found no relationship and 3 found only a weak relationship of neonatal administration of intramuscular or intravenous vitamin K with the risk of solid childhood tumors or leukemia.

    Recent research on the pathogenesis of childhood leukemia additionally weakens the plausibility of a causal relationship between parenteral administration of vitamin K and cancer. Investigations by Wiemels et al15 suggest a prenatal origin of childhood leukemia. They found an acute lymphocytic leukemia-associated gene in 12 children with newly diagnosed acute lymphocytic leukemia and postulated that an in utero chromosomal translocation event combined with a postnatal promotional event results in clinical leukemia. Although intramuscular administration of vitamin K could conceivably be a postnatal promotional event, a genetic etiologic explanation further lessens the likelihood of a clinically significant relationship between intramuscular administration of vitamin K and leukemia.

    There is concern that adequate vitamin K prophylaxis be provided to the increasing numbers of newborns who are breastfed exclusively to avoid an increased risk of late VKDB with its associated intracranial hemorrhage.7

    RECOMMENDATIONS

    Because parenteral vitamin K has been shown to prevent VKDB of the newborn and young infant and the risks of cancer have been unproven, the American Academy of Pediatrics recommends the following:

    1. Vitamin K1 should be given to all newborns as a single, intramuscular dose of 0.5 to 1 mg.16

    2. Additional research should be conducted on the efficacy, safety, and bioavailability of oral formulations and optimal dosing regimens of vitamin K to prevent late VKDB.

    3. Health care professionals should promote awareness among families of the risks of late VKDB associated with inadequate vitamin K prophylaxis from current oral dosage regimens, particularly for newborns who are breastfed exclusively.

    Committee on Fetus and Newborn, 2002–2003

    Lillian Blackmon, MD, Chairperson

    Daniel G. Batton, MD

    Edward F. Bell, MD

    William A. Engle, MD

    William P. Kanto, Jr, MD

    Gilbert I. Martin, MD

    Warren Rosenfeld, MD

    Ann R. Stark, MD

    *Carol A. Miller, MD

    Past Committee Member

    Liaisons

    Keith J. Barrington, MD

    Canadian Paediatric Society

    Tonse Raju, MD, DCH

    National Institutes of Health

    Laura E. Riley, MD

    American College of Obstetricians and Gynecologists

    Kay M. Tomashek, MD

    Centers for Disease Control and Prevention

    Carol Wallman, MSN, RNC, NNP

    National Association of Neonatal Nurses

    Staff

    Jim Couto, MA

    *Lead author

    VKDB, vitamin K deficiency bleeding

    REFERENCES

    1. ↵
      American Academy of Pediatrics, Committee on Nutrition. Vitamin K compounds and the water-soluble analogues: use in therapy and prophylaxis in pediatrics. Pediatrics.1961;28 :501– 507
      OpenUrlAbstract/FREE Full Text
    2. ↵
      von Kreis R, Hanawa Y. Neonatal vitamin K prophylaxis. Report of Scientific and Standardization Subcommittee on Perinatal Haemostasis. Thromb Haemost.1993;69 :293– 295
      OpenUrlPubMedWeb of Science
    3. ↵
      Motohara K, Endo F, Matsuda I. Screening for late neonatal vitamin K deficiency by acarboxyprothrombin in dried blood spots. Arch Dis Child.1987;62 :370– 375
      OpenUrlAbstract/FREE Full Text
    4. ↵
      O’Connor ME, Addiego JE Jr. Use of oral vitamin K1 to prevent hemorrhagic disease of the newborn infant. J Pediatr.1986;108 :616– 619
      OpenUrlCrossRefPubMedWeb of Science
    5. McNinch AW, Upton C, Samuels M, et al. Plasma concentrations after oral or intramuscular vitamin K1 in neonates. Arch Dis Child.1985;60 :814– 818
      OpenUrlAbstract/FREE Full Text
    6. ↵
      Schubiger G, Gruter J, Shearer MJ. Plasma vitamin K1 and PIVKA-II after oral administration of mixed-micellar or cremophor EL-solubilized preparations of vitamin K1 to normal breast-fed newborns. J Pediatr Gastroenterol Nutr.1997;24 :280– 284
      OpenUrlCrossRefPubMedWeb of Science
    7. ↵
      Cornelissen M, Von Kries R, Loughnan P, Schubiger G. Prevention of vitamin K deficiency bleeding: efficacy of different multiple oral dose schedules of vitamin K. Eur J Pediatr.1997;156 :126– 130
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      von Kries R, Hachmeister A, Gobel U. Can 3 oral 2 mg doses of vitamin K effectively prevent late vitamin K deficiency bleeding? Eur J Pediatr.1999;158(suppl 3) :S183– S186
      OpenUrl
    9. ↵
      Draper GJ, Stiller CA. Intramuscular vitamin K and childhood cancer. BMJ.1992;305 :709
      OpenUrl
    10. ↵
      Golding J, Paterson M, Kinlen LJ. Factors associated with childhood cancer in a national cohort study. Br J Cancer.1990;62 :304– 308
      OpenUrlCrossRefPubMedWeb of Science
    11. ↵
      Golding J, Greenwood R, Birmingham K, Mott M. Childhood cancer, intramuscular vitamin K, and pethidine given during labour. BMJ.1992;305 :341– 346
      OpenUrlAbstract/FREE Full Text
    12. ↵
      American Academy of Pediatrics, Vitamin K Ad Hoc Task Force. Controversies concerning vitamin K and the newborn. Pediatrics.1993;91 :1001– 1003
      OpenUrlAbstract/FREE Full Text
    13. ↵
      Devesa SS, Silverman DT, Young JL Jr, et al. Cancer incidence and mortality trends among whites in the United States, 1947–84. J Natl Cancer Inst.1987;79 :701– 770
      OpenUrlPubMedWeb of Science
    14. ↵
      Ross JA, Davies SM. Vitamin K prophylaxis and childhood cancer. Med Pediatr Oncol.2000;34 :434– 437
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet.1999;354 :1499– 1503
      OpenUrlCrossRefPubMedWeb of Science
    16. ↵
      American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care. 3rd ed. Washington, DC: American College of Obstetricians and Gynecologists; 1992
    • Copyright © 2003 by the American Academy of Pediatrics
    View Abstract
    PreviousNext

     

    Advertising Disclaimer »

    View this article with LENS
    PreviousNext
    Email

    Thank you for your interest in spreading the word on Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Controversies Concerning Vitamin K and the Newborn
    (Your Name) has sent you a message from Pediatrics
    (Your Name) thought you would like to see the Pediatrics web site.

    Alerts
    Sign In to Email Alerts with your Email Address
    Citation Tools
    Controversies Concerning Vitamin K and the Newborn
    Committee on Fetus and Newborn
    Pediatrics Jul 2003, 112 (1) 191-192; DOI: 10.1542/peds.112.1.191

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Controversies Concerning Vitamin K and the Newborn
    Committee on Fetus and Newborn
    Pediatrics Jul 2003, 112 (1) 191-192; DOI: 10.1542/peds.112.1.191
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Print
    PDF
    Insight Alerts
    • Table of Contents
    • Current Policy
    • Early Release
    • Current Issue
    • Past Issues
    • Editorial Board
    • Editorial Policies
    • Overview
    • Features Video
    • Open Access
    • Pediatric Collections
    • Video Abstracts
    • Author Guidelines
    • Reviewer Guidelines
    • Submit My Manuscript

    Subjects

    • Current Policy
    • Fetus/Newborn Infant
      • Fetus/Newborn Infant
    • AAP Policy Collections by Authoring Entities
      • Committee on Fetus & Newborn
    Back to top

                

    Copyright © 2019 by American Academy of Pediatrics

    International Access »

    Terms of Use
    The American Academy of Pediatrics (AAP) takes the issue of privacy very seriously. See our Privacy Statement for information about how AAP collects, uses, safeguards and discloses the information collected on our Website from visitors and by means of technology.
    FAQ

     

    AAP Pediatrics